An interventional study of Feedback Report in Depressive Disorders, Depressive Symptoms and Anxiety Disorders and Symptoms, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-07.
Sponsored by Stanford University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Depressive Disorder by Stanford University — none open to participants now, none under way, none of them phase 3. Depressive Disorder · Stanford University.
Among the 13 studies in Depressive Disorder by Stanford University, this one is one of 2 that started in 2017, is one of 6 with no phase, and was the 11th registered.
855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.
Browse Depressive Disorder studies →None of the 13 studies in Depressive Disorder by Stanford University is open now. The open studies under Depressive Disorder, anywhere →
Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2
First in 1998; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 88 across 689 interventional studies indexed under Depressive Disorder.
Median enrollment 22 across the 8 interventional studies, 500 across the 5 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,170 studies on the registry; 433 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Depressive Disorder by Stanford University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a demonstration project focused on translating neuroscience insights into clinical practice. The researchers will evaluate how neuroscience assessments may be applied in the clinical setting to help inform care decisions. The aim of the study is to undertake a pragmatic pilot trial to assess whether the inclusion of structured feedback from neuroscience assessments has an effect on improving patient outcomes. The study will investigate how neuroscience assessments can be integrated into and improve clinical care. The impact of sharing information and conclusions from these assessments with psychiatric providers will be explored. Outcomes will include symptoms, social/occupational function and qualify of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. Participants randomized to the Feedback Group will have the results of this assessment shared with their psychiatric treatment team before they begin treatment. This data will be used at the full discretion of the treatment team to inform personalized treatment options. All treatment decisions remain up to the treatment providers and patient.
Other: Feedback Report
All participants in the study will undergo a comprehensive neuroscience assessment including clinical questionnaires, a structured diagnostic interview, neuropsychological assessment, genetic testing, and structural and functional MRI. However, participants randomized to the Delayed Feedback Group will not have the results of this assessment shared with their treatment team until the end of their participation in this study (12 weeks).
A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
Patient Health Questionnaire (PHQ-9)
A 9-item questionnaire of self-reported symptoms of major depression commonly used in research and routine clinical care
Time frame: 12 weeks
Generalized Anxiety Disorder Questionnaire (GAD-7)
A 7-item questionnaire of self-reported symptoms of generalized anxiety commonly used in research and routine clinical care
Time frame: 12 weeks
Sheehan Disability Scale (SDS) of Social/Occupational Functioning
Level of functioning in social, occupational, and home life domains
Time frame: 12 weeks
Frequency, Intensity, and Burden of Side Effects Ratings (FIBSER)
Burden of side effects from psychiatric medication
Time frame: 12 weeks
Ran from Jul 2017 to primary completion in Dec 2019, 28 months.
Of 261 non-industry interventional studies with no phase under Depressive Disorder, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's 28 months is close to that.
Counting every sponsor, half of 275 studies reached it within 29 months; a quarter within 15 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.